K V Pharmaceutical Co. Class A (NYSE:KV-A)

CAPS Rating: 2 out of 5

Develops advanced drug delivery technologies which enhance the effectiveness of new therapeutic agents, existing pharmaceutical products and prescription nutritional products.

Recs

0
Player Avatar robertshrestha (46.17) Submitted: 4/29/2011 9:19:01 AM : Underperform Start Price: $4.07 KV-A Score: +64.59

Too much uncertainty right now, still coming under heavy fire, significant price drop on Makena will hurt margins going forward, stock still up quite a bit since FDA approval (even with recent plunge). Too risky for my blood.

Featured Broker Partners


Advertisement